MGD 007

Drug Profile

MGD 007

Alternative Names: gpA33 x CD3; MGD-007

Latest Information Update: 29 Oct 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MacroGenics
  • Developer MacroGenics; Servier
  • Class Antineoplastics; Bispecific antibodies; Proteins
  • Mechanism of Action CD3 antigen inhibitors; Membrane glycoprotein inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Colorectal cancer
  • Preclinical Gastrointestinal cancer

Most Recent Events

  • 01 Sep 2014 Phase-I clinical trials in Colorectal cancer (Late-stage disease) in USA (Parenteral) (NCT02248805)
  • 29 Jul 2014 MGD 007 licensed to Servier worldwide, excluding North America, South Korea, Japan and India
  • 06 Apr 2014 Pharmacodynamics data from a preclinical studies in Gastrointestinal cancer presented at the 105th Annual Meeting of the American Association for Cancer Research (AACR-2014)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top